MANAGEMENT TEAM

Dr. Himabindu Gaddipati is a practicing Oncologist in San Diego, CA. After graduating from Andhra Medical College, Visakhapatnam in 1999 she pursued 8 years of post-graduate training at University of Virginia in the United States. She completed Internal Medicine residency followed by post-doc fellowships in Genetics and Molecular Biology from the University of Pennsylvania, PA and Hematology/Oncology from University Hospitals/Case Western Reserve University. She served as a visiting scientist at the Wistar Research Institute. She was subsequently trained as an Interagency Taskforce Oncology Product Development post-doc fellow at the National Cancer Institute, Bethesda and The Food and Drug Administration (FDA). She gained valuable insight about the regulatory requirements for marketing approval of drugs in the division of oncology at the FDA. At the National Cancer Institute, she served as an analyst for the Federal Small Business Innovation Research (SBIR Program) and also completed a certificate program in Technology Transfer. She also obtained a solid overview about the process of technology commercialization at the Wharton School of Business where she completed her Master’s Degree. She is currently the co-chairperson  for the Biocom oncology group, a network of more than 120 organizations including hospitals, research institutions, companies and foundations engaged in cancer related activities in the Southern California.

Dr. Himabindu Gaddipati
Dr. Himabindu Gaddipati, MD, EMTM

Chairman and Managing Director

Dr. Himabindu Gaddipati
Dr. Himabindu Gaddipati

MD, EMTM

Chairman and Managing Director

Dr. Mandar Kulkarni
Dr. Mandar Kulkarni, PhD

Chief Executive Officer

Dr. Mandar Kulkarni
Dr. Mandar Kulkarni
PhD

Chief Executive Officer

After earning his doctorate in molecular carcinogenesis from Purdue University, Dr. Kulkarni was selected to become a T32 fellow at the Yale School of Medicine and was awarded a young scientist award for his work in the structural biology and signal transduction. As a senior scientist at M/Z Diagnostics, he managed business, obtained an NIH-SBIR grant as a PI, and was awarded a Young scientist award by the FSG. At Sandor Lifesciences, as the Head of Molecular Biology and Genomics, he designed and executed numerous NGS, microarray and bioinformatics projects. Then, as the Chief Technology Officer at CGIndia, he managed all operations and lead the development of research services, diagnostics, biopharma services, R&D, and genomics-based clinical assays in the area of precision oncology. He was also responsible for ensuring the financial success of the Indian business unit and established several high value collaborations in the Indian personalized oncology space. Currently, he is also a key member of the senior executive team and drives the scientific agenda at Lumiseek.

Mr. Natarajan holds dual Masters’ Degrees in Chemistry & Pharmacokinetics from Birla Institute of Technology & Sciences, Pilani and Medical College of Virginia, VA, USA. Mr. Sreevatsa Natarajan is a scientist-entrepreneur with more than 15 years of global R&D and business experience in the life sciences industry. He has held leadership positions across various domains in companies such as Purdue Pharma, Vertex Pharma, Glenmark Pharma and Aurigene. He has played key roles in developing & launching several novel drugs across various therapeutic areas such as inflammation, infectious diseases, neurology etc. Mr. Natarajan brings extensive experience on the science side in applying pharmacology & pharmacokinetics to drug development problems and on the business side in structuring deals and facilitating collaborative alliances in a global context.

Mr. Sreevatsa Natarajan
Mr. Sreevatsa Natarajan, MS

Chief Business Adviser

Mr. Sreevatsa Natarajan
Mr. Sreevatsa Natarajan

MS

Chief Business Adviser

Dr. Loganathan Doraisamy, MSc, PhD

Chief Technology Officer

Dr. Loganathan Doraisamy
MSc, PhD

Chief Technology Officer

Dr. Doraisamy has expertise in the areas of nano-bio technologies, biomarker detection, microfluidics and next generation sequencing technologies for healthcare and bio-defense. He has successfully led collaborations between various stakeholders such as biotech industry, university researchers, clinical and government laboratories, US government funding agencies, private investors and customers, enabling R&D, product development and commercialization.

 

Dr. Keswarpu possesses over 20 years of professional health science experience as a Physician Scientist and also held numerous leadership positions and has driven product innovations in healthcare while utilizing her clinical knowledge of pathology and oncology. She earned a postgraduate degree as an M.D. in Pathology from St. John’s Medical College in India and a DNB in Pathology from the National Board of Exams in India. She also holds Bachelor of Medicine and Bachelor of Surgery degrees from MKCG Medical College in India. Additionally, she completed the Executive Program at the Indian School of Business. Dr. Keswarpu has been granted multiple patents and has published scientific articles in many journals. She is also the recipient of major awards and honors for her work in academic settings and during her engagements in corporate roles.

Payal
Dr. Payal Keswarpu, MD

Lab Director – Pathology

Payal
Dr. Payal Keswarpu

MD

Lab Director – Pathology

Dr. Shruti Krishnan PhD

R&D and Alliance Manager

Tabitha Pothula
Ms. Tabitha Pothula Pharma MBA

Senior Project Manager

Satish Chokka MBA

Operations Manager

Ms. Lekhasree C B.tech (Biotech)

Junior Scientist

cancer research, discover, cure, clinical